lerapolturev

AXP000124.1 · Oncolytic virus

Platform
poliovirus (Sabin type 1 with HRV2 IRES)
Originator
Duke University (Matthias Gromeier)
Sponsor
Istari Oncology

Names

NameTypeSource
lerapolturevpreferred name, INNcurator, ncit
PVSRIPOcodencit

Virus

Role
Oncolytic
Family
Picornaviridae
Virus
poliovirus 1 (NCBI Taxonomy 12080)
Strain
Sabin type 1 with HRV2 IRES
Replication
replicating
Modifications
cognate IRES replaced by the human rhinovirus 2 IRES (PVSRIPO chimera)
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C184921
FDA UNII
MQ5GV2WUK4

Approvals

No regulatory approval recorded.

Clinical trials (12)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06177964Lerapolturev (PVSRIPO) in GBMRecruitingPhase 22024-07-152029-0292Recurrent Supratentorial Glioblastoma
NCT04690699LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint InhibitorsTerminatedPhase 1/22021-08-012024-04-044Bladder Cancer; Non-muscle-invasive Bladder Cancer; Solid Tumor
NCT04577807LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory MelanomaCompletedPhase 22020-11-172024-11-1527Melanoma
NCT04479241LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent GlioblastomaCompletedPhase 22020-10-212024-06-0525Brain Tumor; Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma
NCT04125719PVSRIPO in Combination With Nivolumab in MelanomaWithdrawnPhase 12020-06-012024-10-010Melanoma
NCT03973879Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaWithdrawnPhase 1/22020-022024-010Malignant Glioma
NCT03564782Examining Bioactivity of PVSRIPO in Invasive Breast CancerCompletedEarly phase 12019-06-302022-04-115Invasive Breast Cancer
NCT03712358PVSRIPO for Patients With Unresectable MelanomaTerminatedPhase 12018-11-262021-03-2312Melanoma
NCT03043391Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in ChildrenCompletedPhase 12017-11-072022-03-238Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Atypical Teratoid/Rhabdoid Tumor of Brain; Embryonal Tumor of Brain; Ependymoma; Glioblastoma; Gliosarcoma; Malignant Glioma; Medulloblastoma; Pleomorphic Xanthoastrocytoma of Brain
NCT02986178Lerapolturev in Recurrent Malignant GliomaCompletedPhase 22017-06-012022-09-30121Malignant Glioma
NCT01491893PVSRIPO for Recurrent Glioblastoma (GBM)CompletedPhase 12012-04-252017-06-2761GBM; Glioblastoma; Glioma; Malignant Glioma
NCT04599647EAP for the Treatment of Glioblastoma With PVSRIPONo longer availableGlioblastoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38215438The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.Journal of neurosurgery. Pediatrics2024cited by trial NCT03043391
PMID 37004712Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.The Lancet. Child & adolescent health2023cited by trial NCT03043391
PMID 37072349Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.Journal for immunotherapy of cancer2023cited by trial NCT01491893
PMID 36175036Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma.Journal for immunotherapy of cancer2022cited by trial NCT03712358
PMID 33875611Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.Journal for immunotherapy of cancer2021cited by trial NCT03712358
PMID 29943666Recurrent Glioblastoma Treated with Recombinant Poliovirus.The New England journal of medicine2018cited by trial NCT01491893

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41532826Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses.Cancer immunology research2026name in abstract: PVSRIPO
PMID 41705010A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy.Cureus2026name in abstract: PVSRIPO
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: PVSRIPO
PMID 41993267Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris.bioRxiv : the preprint server for biology2026name in abstract: PVSRIPO
PMID 42994380Overcoming glioma heterogeneity: Strategies to improve the specificity of oncolytic viruses.Pathology, research and practice2026name in abstract: PVSRIPO
PMID 40313264Lymphotropic Virotherapy Engages DC and High Endothelial Venule Inflammation to Mediate Cancer In Situ Vaccination.medRxiv : the preprint server for health sciences2025name in abstract: PVSRIPO
PMID 40957170Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.International immunopharmacology2025name in abstract: PVSRIPO
PMID 41108331The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025name in abstract: lerapolturev
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: PVSRIPO
PMID 41372729Emerging therapies for glioblastoma.Journal of neuro-oncology2025name in abstract: PVSRIPO
PMID 38183802Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma.Translational oncology2024name in abstract: PVSRIPO
PMID 38689623Focus on current and emerging treatment options for glioma: A comprehensive review.World journal of clinical oncology2024name in abstract: lerapolturev
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: PVSRIPO
PMID 36301489CD155 is a putative therapeutic target in medulloblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023name in abstract: PVSRIPO
PMID 36494005Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.Annals of oncology : official journal of the European Society for Medical Oncology2023name in abstract: PVSRIPO
PMID 36510843Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy2023name in abstract: PVSRIPO
PMID 36864784Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.Neuro-oncology2023name in abstract: PVSRIPO
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: PVSRIPO
PMID 37962360Early enterovirus translation deficits extend viral RNA replication and elicit sustained MDA5-directed innate signaling.mBio2023name in abstract: PVSRIPO
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: PVSRIPO
PMID 35487285Clinical advances in oncolytic virotherapy for pediatric brain tumors.Pharmacology & therapeutics2022name in abstract: PVSRIPO
PMID 35652592PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling.mBio2022name in abstract: PVSRIPO
PMID 33771666Oncolytic virus in gliomas: a review of human clinical investigations.Annals of oncology : official journal of the European Society for Medical Oncology2021name in abstract: PVSRIPO
PMID 34277838Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine2021name in abstract: PVSRIPO
PMID 31988324Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.Nature communications2020name in abstract: PVSRIPO
PMID 31428153Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy.Journal of oncology2019name in abstract: PVSRIPO
PMID 29414253Recombinant Poliovirus for Cancer Immunotherapy.Annual review of medicine2018name in abstract: PVSRIPO
PMID 29878245Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.Journal of neuropathology and experimental neurology2018name in abstract: PVSRIPO
PMID 29997212Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.Journal of virology2018name in title: PVSRIPO
PMID 30563098Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?Cancers2018name in abstract: PVSRIPO
PMID 28829151Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.Archives of pathology & laboratory medicine2017name in abstract: PVSRIPO
PMID 28931654Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.Science translational medicine2017name in abstract: PVSRIPO
PMID 27806313Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.Oncotarget2016name in title: PVSRIPO
PMID 28203321The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.American journal of virology2016name in abstract: PVSRIPO
PMID 26083317Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.Current opinion in virology2015name in abstract: PVSRIPO
PMID 24939611Oncolytic polio virotherapy of cancer.Cancer2014name in abstract: PVSRIPO
PMID 25187540Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis.Journal of virology2014name in abstract: PVSRIPO
PMID 25187541Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.Journal of virology2014name in abstract: PVSRIPO
PMID 22171271Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis.Journal of virology2012name in abstract: PVSRIPO
PMID 21984883Oncolytic poliovirus against malignant glioma.Future virology2011name in abstract: PVSRIPO
PMID 20299272Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.Cytokine & growth factor reviews2010name in abstract: PVSRIPO
PMID 20648000MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus.Molecular therapy : the journal of the American Society of Gene Therapy2010name in abstract: PVSRIPO
PMID 18951922Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.Journal of virological methods2009name in abstract: PVSRIPO
PMID 18098139Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.Journal of medical virology2008name in abstract: PVSRIPO
PMID 16489093Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in abstract: PVSRIPO

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA281320Resolving Spatiotemporal Dynamics of Recombinant Poliovirus ImmunotherapyDUKE UNIVERSITYGROMEIER, MATTHIAS2023–2026name in abstract: PVSRIPO
R01NS108773Innate Antiviral Signals for Cancer ImmunotherapyDUKE UNIVERSITYGROMEIER, MATTHIAS2018–2026name in abstract: PVSRIPO
R37CA315608Innate immune memory for glioma immunotherapyDUKE UNIVERSITYBROWN, MICHAEL CLAVON2026–2026name in abstract: PVSRIPO
K08CA237726PVSRIPO in melanomaDUKE UNIVERSITYBEASLEY, GEORGIA2020–2024name in title: PVSRIPO
P01CA225622Biostatistics and Bioinformatics CoreDUKE UNIVERSITYHERNDON, JAMES E2018–2022name in title: PVSRIPO
F32CA224593Cancer Immunotherapy Through Intratumoral Activation of Recall ResponsesDUKE UNIVERSITYBROWN, MICHAEL CLAVON2018–2020name in abstract: PVSRIPO
R21NS112899Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?DUKE UNIVERSITYASHLEY, DAVID M.2019–2019name in abstract: PVSRIPO
P50CA190991Oncolytic Immunotherapy of Malignant GliomaDUKE UNIVERSITYGROMEIER, MATTHIAS2014–2018name in abstract: PVSRIPO

Notes

Live attenuated Sabin type 1 poliovirus whose internal ribosome entry site is replaced by that of human rhinovirus type 2, removing neurovirulence. Given intratumorally, into glioma by convection-enhanced delivery.

How to cite

lerapolturev (AXP000124.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000124.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.